Emma Simpson

Emma Simpson

Auto-generated profile, based on publicly available information

Emma Simpson

University of Sheffield Sheffield UK

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Health Technology Assessment
Verified
Journal Article
Closed access
SDSarah Davis
Sarah Davis
ESEmma Simpson
Emma Simpson
JHJean Hamilton
Jean Hamilton
MJMarrissa Martyn-St James
Marrissa Martyn-St James
ARAndrew Rawdin
Andrew Rawdin
PSPeter Selby
Peter Selby
Background: Fragility fractures are fractures that result from mechanical forces that would not ordinarily result in fracture.Objectives: The objectives were to evaluate the clinical effectiveness, safety and cost-effectiveness of non-bisphosphonates {denosumab [Prolia®; Amgen Inc., Thousand Oaks, CA, USA], raloxifene [Evista®; Daiichi Sankyo Company, Ltd, Tokyo, Japan], romosozumab [Evenity®; Union Chimique Belge (UCB) S.A. (Brussels, Belgium) and Amgen Inc.] and teriparatide [Forsteo®; Eli Lilly and Company, Indianapolis, IN, USA]}, compared with each other, bisphosphonates or no treatment, for the prevention of fragility fracture.Data sources: For the clinical effectiveness review, nine electronic databases (including MEDLINE, EMBASE and the World Health Organization International Clinical Trials Registry Platform) were searched up to July 2018.Review methods: A systematic review and network meta-analysis of fracture and femoral neck bone mineral density were conducted. A review of published economic analyses was undertaken and a model previously used to evaluate bisphosphonates was adapted. Discrete event simulation was used to estimate lifetime costs and quality-adjusted life-years for a simulated cohort of patients with heterogeneous characteristics. This was done for each non-bisphosphonate treatment, a strategy of no treatment, and the five bisphosphonate treatments previously evaluated. The model was populated with effectiveness evidence from the systematic review and network meta-analysis. All other parameters were estimated from published sources. An NHS and Personal Social Services perspective was taken, and costs and benefits were discounted at 3.5% per annum. Fracture risk was estimated from patient characteristics using the QFracture®(QFracture-2012 open source revision 38, Clinrisk Ltd, Leeds, UK) and FRAX®(web version 3.9, University of Sheffield, Sheffield, UK) tools. The relationship between fracture risk and incremental net monetary benefit was estimated using non-parametric regression. A probabilistic sensitivity analysis and scenario analyses were used to assess uncertainty.Results: Fifty-two randomised controlled trials of non-bisphosphonates were included in the clinical effectiveness systematic review and an additional 51 randomised controlled trials of bisphosphonates were included in the network meta-analysis. All treatments had beneficial effects compared with placebo for vertebral, non-vertebral and hip fractures, with hazard ratios varying from 0.23 to 0.94, depending on treatment and fracture type. The effects on vertebral fractures and the percentage change in bone mineral density were statistically significant for all treatments. The rate of serious adverse events varied across trials (0–33%), with most between-group differences not being statistically significant for comparisons with placebo/no active treatment, non-bisphosphonates or bisphosphonates. The incremental cost-effectiveness ratios were > £20,000 per quality-adjusted life-year for all non-bisphosphonate interventions compared with no treatment across the range of QFracture and FRAX scores expected in the population eligible for fracture risk assessment. The incremental cost-effectiveness ratio for denosumab may fall below £30,000 per quality-adjusted life-year at very high levels of risk or for high-risk patients with specific characteristics. Raloxifene was dominated by no treatment (resulted in fewer quality-adjusted life-years) in most risk categories.Limitations: The incremental cost-effectiveness ratios are uncertain for very high-risk patients.Conclusions: Non-bisphosphonates are effective in preventing fragility fractures, but the incremental cost-effectiveness ratios are generally greater than the commonly applied threshold of £20,000–30,000 per quality-adjusted life-year.Study registration: This study is registered as PROSPERO CRD42018107651.Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full inHealth Technology Assessment; Vol. 24, No. 29. See the NIHR Journals Library website for further project information.

1 January 2020 in Bone
Verified
Journal Article
Closed access
ESE.L. Simpson
E.L. Simpson
MJMarrissa Martyn-St James
Marrissa Martyn-St James
JHJean Hamilton
Jean Hamilton
RWRuth Wong
Ruth Wong
NGNeil Gittoes
Neil Gittoes
SDSarah Davis
Sarah Davis

1 April 2018 in Health Technology Assessment
Verified
Journal Article
Closed access
ESEmma Simpson
Emma Simpson
EHEmma Hock
Emma Hock
MSMatt Stevenson
Matt Stevenson
RWRuth Wong
Ruth Wong
NDNaila Dracup
Naila Dracup
RWRichard Wakefield
Richard Wakefield
Background: Synovitis (inflamed joint synovial lining) in rheumatoid arthritis (RA) can be assessed by clinical examination (CE) or ultrasound (US). Objective: To investigate the added value of US, compared with CE alone, in RA synovitis in terms of clinical effectiveness and cost-effectiveness. Data sources: Electronic databases including MEDLINE, EMBASE and the Cochrane databases were searched from inception to October 2015. Review methods: A systematic review sought RA studies that compared additional US with CE. Heterogeneity of the studies with regard to interventions, comparators and outcomes precluded meta-analyses. Systematic searches for studies of cost-effectiveness and US and treatment-tapering studies (not necessarily including US) were undertaken. Mathematical model: A model was constructed that estimated, for patients in whom drug tapering was considered, the reduction in costs of disease-modifying anti-rheumatic drugs (DMARDs) and serious infections at which the addition of US had a cost per quality-adjusted life-year (QALY) gained of £20,000 and £30,000. Furthermore, the reduction in the costs of DMARDs at which US becomes cost neutral was also estimated. For patients in whom dose escalation was being considered, the reduction in number of patients escalating treatment and in serious infections at which the addition of US had a cost per QALY gained of £20,000 and £30,000 was estimated. The reduction in number of patients escalating treatment for US to become cost neutral was also estimated. Results: Fifty-eight studies were included. Two randomised controlled trials compared adding US to a Disease Activity Score (DAS)-based treat-to-target strategy for early RA patients. The addition of power Doppler ultrasound (PDUS) to a Disease Activity Score 28 joints-based treat-to-target strategy in the Targeting Synovitis in Early Rheumatoid Arthritis (TaSER) trial resulted in no significant between-group difference for change in Disease Activity Score 44 joints (DAS44). This study found that significantly more patients in the PDUS group attained DAS44 remission (p = 0.03). The Aiming for Remission in Rheumatoid Arthritis (ARCTIC) trial found that the addition of PDUS and grey-scale ultrasound (GSUS) to a DAS-based strategy did not produce a significant between-group difference in the primary end point: composite DAS of < 1.6, no swollen joints and no progression in van der Heijde-modified total Sharp score (vdHSS). The ARCTIC trial did find that the erosion score of the vdHS had a significant advantage for the US group (p = 0.04). In the TaSER trial there was no significant group difference for erosion. Other studies suggested that PDUS was significantly associated with radiographic progression and that US had added value for wrist and hand joints rather than foot and ankle joints. Heterogeneity between trials made conclusions uncertain. No studies were identified that reported the cost-effectiveness of US in monitoring synovitis. The model estimated that an average reduction of 2.5% in the costs of biological DMARDs would be sufficient to offset the costs of 3-monthly US. The money could not be recouped if oral methotrexate was the only drug used. Limitations: Heterogeneity of the trials precluded meta-analysis. Therefore, no summary estimates of effect were available. Additional costs and health-related quality of life decrements, relating to a flare following tapering or disease progression, have not been included. The feasibility of increased US monitoring has not been assessed. Conclusion: Limited evidence suggests that US monitoring of synovitis could provide a cost-effective approach to selecting RA patients for treatment tapering or escalation avoidance. Considerable uncertainty exists for all conclusions. Future research priorities include evaluating US monitoring of RA synovitis in longitudinal clinical studies. Study registration: This study is registered as PROSPERO CRD42015017216. Funding: The National Institute for Health Research Health Technology Assessment programme.

5 July 2025 in British Journal of Psychology
Verified
Journal Article
Open access
ESEmma Simpson
Emma Simpson
CCChristopher Carroll
Christopher Carroll
ASAnthea Sutton
Anthea Sutton
JFJessica Forsyth
Jessica Forsyth
ARAnnabel Rayner
Annabel Rayner
EWEmily Wood
Emily Wood
The objective was to provide up‐to‐date clinical and cost‐effectiveness evidence investigating eye movement desensitization and reprocessing (EMDR) for treatment or prevention of adult post‐traumatic stress disorder (PTSD). We conducted a systematic review of randomized controlled trials (RCTs) and cost‐effectiveness studies assessing PTSD symptoms in adults, published since the NICE 2018 guidelines. EMDR was compared with trauma‐focused‐cognitive behavioural therapy (TF‐CBT), waitlist or usual care. Six databases were searched in September 2023. Risk of bias was assessed. Data synthesis included Bayesian meta‐analyses of standardized mean differences if sufficient data were available from at least three RCTs. From 2038 records, 17 studies met the eligibility criteria. One modelling‐based study reported cost‐effectiveness, finding EMDR the most cost‐effective intervention compared to 10 others, including TF‐CBT. Sixteen RCTs (n = 1031) providing clinical PTSD outcome data were identified. Most studies had small sample sizes, and all but one was at high/moderate risk of bias. Additionally, 13 RCTs from NICE 2018 guidelines contributed to meta‐analyses. EMDR treatment was generally of shorter duration with a lower burden on patient time. Meta‐analyses found EMDR was statistically significantly better than waitlist/usual care. There was no significant difference in treatment effect between EMDR and TF‐CBT, both reported significantly improved PTSD symptoms.

1 August 2013 in Health Technology Assessment
Verified
Journal Article
Open access
PDF file
ESEL Simpson
EL Simpson
MSM Stevenson
M Stevenson
ASA Scope
A Scope
EPE Poku
E Poku
JMJ Minton
J Minton
PEP Evans
P Evans
Health Technology Assessment Volume: 17, Issue: 36, Published in August 2013

20 March 2013 in PharmacoEconomics
Verified
Journal Article
Closed access
PDF file
ESE. L. Simpson
E. L. Simpson
PFP. Fitzgerald
P. Fitzgerald
PEP. Evans
P. Evans
PTP. Tappenden
P. Tappenden
NKN. Kalita
N. Kalita
ABA. Bakhai
A. Bakhai